Pancreatic cancer

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#FDA #Oncology #Pancreatic cancer #Revolution Medicines

FDA approves RAS-targeted drug for metastatic pancreatic cancer

The US Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC).  It is approved in patients who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.  The… Read More

#Editor's Choice #News #Regulatory

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Oncology #Pancreatic cancer #The University of Texas at Austin

Research uncovers driver of CAR-T resistance in solid tumours

Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies.  CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cells
#Funding #Oncology #Pancreatic cancer

$6.7m awarded to pancreatic cancer research projects

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is awarding $6.7 million to eight projects in 2026.  The funded projects span the full continuum of pancreatic cancer research, from prevention and early detection to next-generation therapies.   “Every investment we make is driven by one goal:… Read More

#Cancer Research #News

#Elicio Therapeutics #KRAS #Oncology #Pancreatic cancer #Phase II trial

Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer

Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS).   However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More

#Cancer Research #News

#Breast cancer #Clinical trial #Oncology #Ovarian cancer #Pancreatic cancer #Prostate cancer

Overcoming drug resistance with General Oncology

DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between… Read More

#Exclusive Content

gut epithelium
#Funding #Metabolic diseases #Pancreatic cancer #Seaport Therapeutics

$15m supports first oral therapy to restore gut lymphatic function

Seaport Therapeutics has received an award of up to $15 million to advance its GlyphCele, from the Advanced Research Projects Agency for Health (ARPA-H), in collaboration with the Monash Institute of Pharmaceutical Sciences (MIPS).  GlyphCele is an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib, which is designed to… Read More

#Business & Investment #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Pancreatic cancer
#Oncology #Pancreatic cancer #Tokyo University of Science #Tumour microenvironment (TME)

Potential tumour-suppressing gene identified in pancreatic cancer

A new study has revealed that low levels of CTDNEP1 may drive early and deadly pancreatic tumours, highlighting its role as a tumour suppressor.  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for… Read More

#Cancer Research #News

Pancreatic cancer
#Clinical trial #Pancreatic cancer

HUTCHMED begins Phase III trial of PDAC treatment 

Biopharmaceutical company HUTCHMED has launched the Phase III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).  PDAC is a highly aggressive form of cancer, representing over 90% of pancreatic cancer cases. Globally, an estimated 511,000 people were diagnosed… Read More

#Cancer Research #News

#Advanced Therapies #Cancer research #Cell therapy #Pancreatic cancer

Tumour-regressing cell therapy advanced towards clinic 

Drug discovery company Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, advancing the treatment to clinic.  Lunai’s Dendritic Cell Combination Therapy (DCCT) achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised pre-clinical models. Read More

#Cancer Research #News

Pancreatic cancer
#iOnctura #Oncology #Pancreatic cancer #Phase I trial

mPDAC treatment reaches primary endpoint in Phase Ib trial

Cambritaxestat, a treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), has met its primary endpoint in a Phase Ib trial. Cambritaxestat, an oral autotaxin (ATX) inhibitor, was evaluated in patients with previously untreated mPDAC. The treatment demonstrated safety, tolerability and anti-tumour responses, with data presented at the European Society… Read More

#Cancer Research #News

#Long Covid #Oncology #Pancreatic cancer

DDW Highlights: 7 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. This week’s news is led by the agreement by Genmab to acquire Merus, an announcement… Read More

#Podcasts

#3D modelling #Career #Interview #Meet the Researcher #Oncology #Pancreatic cancer

Meet the researcher: Catherine Whittington, Associate Professor

DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical Engineering at WPI about her current work and the research that drives her.   DT: Can you tell us what you do and what you’re working on at the moment? CW: I teach classes in the biomedical engineering (BME)… Read More

#Exclusive Content

A laboratory mouse
#Cancer Research Institute #Pancreatic cancer

Scientists discover key protein target to treat pancreatic cancer

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer.  The findings, published in Nature, show that blocking the protein SPP1 could stop the spread of the cancer and increase survival… Read More

#News